California 2019-2020 Regular Session

California Senate Bill SR88 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION Senate Resolution No. 88Introduced by Senator ChangJuly 02, 2020 Relative to the medical supply chain.LEGISLATIVE COUNSEL'S DIGESTSR 88, as introduced, Chang. Digest KeyBill TextWHEREAS, The global pandemic of the novel coronavirus, known as COVID-19, has underscored the vulnerability of the United States and California with respect to the consolidation of medical supply manufacturing in China; andWHEREAS, In October 2019, shortly before the COVID-19 crisis began, Dr. Janet Woodcock, the director of the Center for Drug Evaluation and Research at the United States Food and Drug Administration, testified before the House Committee on Energy and Commerce. Dr. Woodcock stated, Historically, the production of medicines for the U.S. population has been domestically based. However, in recent decades, drug manufacturing has gradually moved out of the United States. Woodcock further stated on the record, the FDAs data show that the number of registered facilities making active pharmaceutical ingredients in China has more than doubled between calendar years 2010 to 2019, inclusive; andWHEREAS, China is known as the biggest producer of medical grade face masks in the world, and the country supplied half of the global supply in the 2018 calendar year; andWHEREAS, According to the Department of Finance, the largest single expenditure by the State of California during the COVID-19 crisis amounted to almost $1 billion in medical grade masks, including desperately needed N95 respirators, from China; andWHEREAS, The consolidation of medical supply chains in China is especially disconcerting as it relates to critical pharmaceuticals; andWHEREAS, The market in the United States is dependent on Chinese pharmaceuticals for 97 percent of antibiotics, 95 percent of ibuprofen, 90 percent of vitamin C, 91 percent of hydrocortisone, 70 percent of acetaminophen, and as much as 45 percent of heparin; andWHEREAS, Concentrated dependency on Chinese suppliers for pharmaceuticals is risky at any time. However, during a global pandemic, this dependency becomes a national security matter. Indeed, the COVID-19 pandemic forced the closure of Chinese pharmaceutical manufacturers, thereby disrupting supply to the United States; andWHEREAS, There is growing bipartisan congressional support for legislative proposals to divert medical supply chains away from China; and WHEREAS, Federal legislation has been introduced that would enact the Protecting our Pharmaceutical Supply Chain from China Act of 2020. This proposal would require a registry to track pharmaceuticals, and would prohibit the federal government and federally qualified health centers from making purchases that include active pharmaceutical ingredients produced in China; now, therefore, be itResolved by the Senate of the State of California, That the Senate urges the President of the United States and the Congress of the United States to fully act within their power to move the United States medical supply chains away from China and create incentives to produce a greater share of pharmaceuticals in the United States; and be it furtherResolved, That the Secretary of the Senate transmit copies of this resolution to the President of the United States, to the Speaker of the House of Representatives, to the Majority Leader of the Senate, to each Senator and Representative from California in the Congress of the United States, and to the author for appropriate distribution.
2	2
3	3	CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION Senate Resolution No. 88Introduced by Senator ChangJuly 02, 2020 Relative to the medical supply chain.LEGISLATIVE COUNSEL'S DIGESTSR 88, as introduced, Chang. Digest Key
4	4
5	5
6	6
7	7
8	8
9	9	CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION
10	10
11	11	Senate Resolution
12	12
13	13	No. 88
14	14
15	15	Introduced by Senator ChangJuly 02, 2020
16	16
17	17	Introduced by Senator Chang
18	18	July 02, 2020
19	19
20	20	Relative to the medical supply chain.
21	21
22	22	LEGISLATIVE COUNSEL'S DIGEST
23	23
24	24	## LEGISLATIVE COUNSEL'S DIGEST
25	25
26	26	SR 88, as introduced, Chang.
27	27
28	28
29	29
30	30	## Digest Key
31	31
32	32	## Bill Text
33	33
34	34	WHEREAS, The global pandemic of the novel coronavirus, known as COVID-19, has underscored the vulnerability of the United States and California with respect to the consolidation of medical supply manufacturing in China; and
35	35
36	36	WHEREAS, In October 2019, shortly before the COVID-19 crisis began, Dr. Janet Woodcock, the director of the Center for Drug Evaluation and Research at the United States Food and Drug Administration, testified before the House Committee on Energy and Commerce. Dr. Woodcock stated, Historically, the production of medicines for the U.S. population has been domestically based. However, in recent decades, drug manufacturing has gradually moved out of the United States. Woodcock further stated on the record, the FDAs data show that the number of registered facilities making active pharmaceutical ingredients in China has more than doubled between calendar years 2010 to 2019, inclusive; and
37	37
38	38	WHEREAS, China is known as the biggest producer of medical grade face masks in the world, and the country supplied half of the global supply in the 2018 calendar year; and
39	39
40	40	WHEREAS, According to the Department of Finance, the largest single expenditure by the State of California during the COVID-19 crisis amounted to almost $1 billion in medical grade masks, including desperately needed N95 respirators, from China; and
41	41
42	42	WHEREAS, The consolidation of medical supply chains in China is especially disconcerting as it relates to critical pharmaceuticals; and
43	43
44	44	WHEREAS, The market in the United States is dependent on Chinese pharmaceuticals for 97 percent of antibiotics, 95 percent of ibuprofen, 90 percent of vitamin C, 91 percent of hydrocortisone, 70 percent of acetaminophen, and as much as 45 percent of heparin; and
45	45
46	46	WHEREAS, Concentrated dependency on Chinese suppliers for pharmaceuticals is risky at any time. However, during a global pandemic, this dependency becomes a national security matter. Indeed, the COVID-19 pandemic forced the closure of Chinese pharmaceutical manufacturers, thereby disrupting supply to the United States; and
47	47
48	48	WHEREAS, There is growing bipartisan congressional support for legislative proposals to divert medical supply chains away from China; and
49	49
50	50	WHEREAS, Federal legislation has been introduced that would enact the Protecting our Pharmaceutical Supply Chain from China Act of 2020. This proposal would require a registry to track pharmaceuticals, and would prohibit the federal government and federally qualified health centers from making purchases that include active pharmaceutical ingredients produced in China; now, therefore, be it
51	51
52	52	Resolved by the Senate of the State of California, That the Senate urges the President of the United States and the Congress of the United States to fully act within their power to move the United States medical supply chains away from China and create incentives to produce a greater share of pharmaceuticals in the United States; and be it further
53	53
54	54	Resolved, That the Secretary of the Senate transmit copies of this resolution to the President of the United States, to the Speaker of the House of Representatives, to the Majority Leader of the Senate, to each Senator and Representative from California in the Congress of the United States, and to the author for appropriate distribution.